IPGaia (IPG) promotes R&D with the aim of acquiring precious intellectual property for the commercialization of new pharmaceuticals, such as composition of matter patents. IPG will select and develop promising research programs and license them out to pharmaceutical companies.
IPG aims to create an ecosystem to assist in the development of new drugs, especially for personalized medicine.
Our mission is to support pharmaceutical companies in the development of a small quantity of a wide variety of drugs to meet the individual medical needs and deliver them quickly, safely, and effectively to as many patients as possible.
| Name of the Company | IPGaia, Inc. | |
|---|---|---|
| Location | 2-5-1 Atago, Minato-ku, Tokyo 105-6236 | |
| Investor | Healthcare New Platform Fund（100％） General Partner; Whiz Partners Inc. | |
| Capital and Capital Reserves | 10 million JPY | |
| Established | October 26th, 2021 | |
| Business Scope |
| |
| Management | President & CEO Chairman | Yasunori Yamaguchi Satoru Iino |
IPGaia, Inc., (“IPG”) and University of California San Diego (“UC San Diego”), based in La Jolla, California, USA, have entered into a Master Collaborative Research and Development Agreement (“this agreement”) dated July 1st, 2022. This agreement establishes a formal framework for the incorporation of promising drug target leads from UC San Diego into IPG’s drug discovery platform. Following UC San Diego’s strong history of partnering with industry to advance drug discovery, the program enables UC San Diego to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. For patients, personalized medicine holds great …
IP Generator, Inc. (Headquarter: Minato Tokyo, President & CEO: Satoru Iino) will change its name to the following as of July 1, 2022, to further strengthen its business foundation with a new management team. 1. Company Name Change New company name：IPGaia, Inc. (Hereinafter, “IPG”) Background ：”Gaia” is a primordial god that has existed since the beginning of the world in ancient Greek mythology. We have decided to name our company “IP Gaia” with the passion to contribute to society by improving medical access and reducing medical costs as a drug discovery platformer that efficiently generates high-quality clinical development candidates from drug seeds, which is a new beginning in Japan. 2. …
Continue reading “Notice of Company Name Change and New President & CEO Assume Office”
IP Generator, Inc., (“IPG”) and National Research and Development Institute, RIKEN (“RIKEN”), based in Saitama, Japan, have entered into a Drug Discovery Alliance Agreement (“this agreement”) dated June 3, 2022. This agreement, executed with the support of RIKEN Innovation Co., Ltd. (RIKEN Innovation), establishes a formal framework for the incorporation of promising drug target leads from RIKEN into IPG’s drug discovery platform. The program enables RIKEN to propose drug seeds to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG aims for the efficient creation of innovative medicines and hopes to contribute to solving global social issues …
Continue reading “IP Generator, Inc. and RIKEN Announce Drug Discovery Alliance Agreement”
